LC-MS/MS-based metabolomics and PK/PD correlation analysis reveal the mechanism of hyperlipidemia treatment with Gastrodia elata fine powder.

Save

Gastrodia elata Blume is used as both a food and a traditional medicine in East Asia. This study evaluated the lipid-lowering effects of G. elata fine powder (GFP) and the associated metabolic responses in Sprague–Dawley rats with high-fat diet (HFD)-induced hyperlipidemia. Thirty-five rats were assigned to seven groups: a normal-diet control, an untreated HFD model, three GFP groups (150, 300, or 500 mg kg−1 per administration, three times daily), and two positive-control groups receiving simvastatin or fenofibrate.

Following a 6 week modeling period and a 2 week intervention, serum biochemical parameters, liver histology, and serum, urinary, and fecal metabolic profiles were assessed using biochemical assays, histological examination, and untargeted liquid chromatography–high-resolution mass spectrometry. A separate cohort of six hyperlipidemic rats received gastrodin (25 mg kg−1) for pharmacokinetic/pharmacodynamic (PK/PD) analysis. Compared with the untreated HFD group, medium- and high-dose GFP improved serum lipid profiles, reduced serum aminotransferase activities, and ameliorated hepatic histopathological changes.

Metabolomic profiling revealed 14 urinary, 8 fecal, and 16 serum metabolites whose HFD-associated alterations shifted toward normal-control levels following high-dose GFP treatment. The associated pathways included phenylalanine metabolism, taurine and hypotaurine metabolism, and the tricarboxylic acid cycle. Gastrodin exhibited a biphasic plasma concentration–time profile, whereas responses of five endogenous metabolic markers lagged behind systemic drug exposure.

These findings support the short-term lipid-lowering activity of GFP in HFD-fed rats and its association with changes in amino acid, bile-acid-related, and energy metabolism.

Introduction

Hyperlipidemia is characterized by elevated circulating concentrations of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), sometimes accompanied by reduced high-density lipoprotein cholesterol (HDL-C). These lipid abnormalities are associated with an increased risk of atherosclerotic cardiovascular disease and frequently coexist with hepatic steatosis, insulin resistance, and chronic low-grade inflammation.1 Although statins, fibrates, and cholesterol absorption inhibitors effectively improve lipid profiles, residual cardiovascular risk and treatment intolerance have prompted interest in food-derived bioactive compounds as potential adjuncts to established lipid-lowering therapies.

Gastrodia elata Blume (Orchidaceae), commonly known as Tianma, is traditionally used as both a medicinal herb and a food in East Asia. Its reported constituents include phenolic glycosides, other aromatic compounds, organic acids, and polysaccharides, with gastrodin serving as a characteristic marker compound.2 Preclinical studies have shown that G. elata extracts can improve insulin resistance in HFD-fed mice and reduce serum cholesterol and hepatic lipid accumulation in HFD-fed rats.3,4 Subacute oral toxicity studies have also provided safety data for a G. elata water extract.5 Together, these findings support further investigation of G. elata as a candidate functional-food or nutraceutical ingredient with potential applications in lipid management. However, the systemic metabolic pathways associated with its lipid-lowering response remain incompletely characterized, particularly for minimally processed fine-powder preparations.

Gastrodia elata contains diverse phytochemicals, including phenolic glycosides and polysaccharides, with gastrodin and 4-hydroxybenzyl alcohol among its reported bioactive constituents.6,7 These constituents and preparations have attracted interest for their potential effects on metabolic disorders. Gastrodin has been reported to improve insulin resistance through PI3K/AKT-dependent regulation of insulin receptor stability.8G. elata extract has also been shown to improve insulin resistance and inflammation while altering gut microbial composition and circulating bile acid profiles in HFD-fed mice.9 More recently, reductions in serum cholesterol and hepatic lipid accumulation were associated with decreased hepatic SREBP-1 expression in HFD-fed rats treated with G. elata extract.10 Together, these findings suggest that insulin signaling, hepatic lipogenesis, and microbiota-associated bile acid metabolism may contribute to the metabolic effects of G. elata. However, the broader metabolic response to GFP treatment remains incompletely characterized.

Metabolomics provides a systems-level view of low-molecular-weight metabolites and can reveal coordinated changes in amino acid, lipid, bile acid, and energy metabolism.11 Multi-matrix profiling of serum, urine, and feces is especially useful because these matrices provide complementary information on circulating metabolism, whole-body excretion, and intestinal metabolic output. Liquid chromatography-mass spectrometry (LC-MS)-based metabolomics has been widely applied to diet-induced hyperlipidemia and to the mechanistic evaluation of botanical products.12–14 Nevertheless, metabolite changes measured at a single terminal time point do not directly explain how exposure to a representative bioactive constituent relates to the onset, magnitude, or delay of the metabolic response.

Pharmacokinetic/pharmacodynamic (PK/PD) modeling can address this gap by relating systemic exposure to time-dependent pharmacological effects. For multicomponent botanical products, integrating exposure data for a representative constituent with pharmacometabolomic effect markers can be informative because responses may be delayed, indirect, or generated by multiple constituents.15

In this study, we combined untargeted high-resolution LC-MS metabolomics with gastrodin PK/PD modeling to evaluate the effects of G. elata fine powder (GFP) in rats with hyperlipidemia induced by a high-fat diet (HFD). We investigated its lipid-lowering activity alongside metabolic changes in serum, urine, and feces. Gastrodin was selected as a representative bioactive constituent for a separate PK/PD experiment to explore relationships between its systemic exposure and selected endogenous metabolite responses.

This complementary approach provides insight into treatment-associated metabolic changes, while the contribution of gastrodin to the overall activity of GFP requires further verification.

Materials and methods

Chemicals, reference standards, and reagents

Gastrodia elata fine powder (GFP; batch No. 220511) was obtained from Yunnan Baiyao Group Zhiyun Health Service Co., Ltd (China). Simvastatin tablets (20 mg per tablet; batch No.

20230418; National Drug Standard H20084420) were manufactured by Shandong Xinqi Pharmaceutical Co., Ltd (China), and fenofibrate tablets (0.1 g per tablet; batch No. 230311; National Drug Standard H31021556) were manufactured by Shanghai Hengshan Pharmaceutical Co., Ltd (China). Gastrodin reference standard (batch No.

N0582) was obtained from Sichuan Hengcheng Zhiyuan Biotechnology Co., Ltd (China). Ferulic acid, resveratrol, taurine, l-phenylalanine, oleamide, and phenylacetylglycine were purchased from Shanghai Macklin Biochemical Technology Co., Ltd (China), and kynurenic acid was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd (China). LC–MS-grade formic acid, methanol, and acetonitrile were obtained from the suppliers specified in the original experimental records.

Ultrapure water was produced using a Milli-Q purification system (Millipore, USA).

Instruments and software

Untargeted metabolomic analyses were performed using an Orbitrap Exploris 120 high-resolution mass spectrometer (Thermo Fisher Scientific, Germany). Targeted quantification was conducted using a SCIEX Triple Quad 7500 LC-MS/MS system equipped with an electrospray ionization source (AB SCIEX, USA). Additional equipment included an XS105 analytical balance (Mettler Toledo, Switzerland), an SB-5200DT ultrasonic cleaner (Ningbo Xinzhi Biotechnology Co., Ltd, China), a 3-18KS refrigerated centrifuge (Sigma, Germany), and a vacuum concentrator (Beijing GIM Technology Co., Ltd, China).

Data were processed using FreeStyle and Compound Discoverer 3.3 (Thermo Fisher Scientific), SIMCA 14.1 (Umetrics, Sweden), Phoenix 8.1 (Certara, USA), SPSS Statistics 25 (IBM, USA), GraphPad Prism 8.0.1 (GraphPad Software, USA), and Origin 2021.

Animals, diet, and ethics

Specific-pathogen-free male Sprague-Dawley rats (170–190 g) were obtained from Beijing Hua Fukang Biotechnology Co., Ltd (production license SCXK [Jing] 2019-0008). Animals were housed under standard laboratory conditions with free access to water and a 12 h light/dark cycle. HFD and control standard chow were obtained from Xiaoshuyoutai (Beijing) Biotechnology Co., Ltd (Laboratory Animal Production License: SCXK (Jing) 2018-0006).

The HFD formula contained basal diet plus 15% lard, 20% sucrose, 5% casein, 1.2% cholesterol and 0.2% sodium cholate, supplemented with minerals, vitamins and other additives. The mass percentages of protein, fat and carbohydrate, energy distribution and total energy density for both diets are listed in SI Table S7. Nutritional parameters were factory-certified assay values.

Animals were acclimatized for 7 days before experimentation. The animal study protocol was approved by the Institutional Animal Care and Use Committee of Hebei Medical University (IACUC-Hebmu-2022134; 28 March 2022).

Preparation of calibration and internal-standard solutions

Gastrodin was dissolved in deionized water to prepare a 2 mg mL−1 stock solution. Working standards were prepared at 1, 10, 20, 50, 100, 150, 200, 250, 300, 350, and 400 ng mL−1. Individual stock solutions of the endogenous standards were prepared at 1 mg mL−1, combined, and diluted to obtain a 0.1 mg mL−1 mixed stock solution.

Working solutions were prepared at 4, 8, 20, 50, 100, 200, 300, and 400 ng mL−1. Ferulic acid and the second internal standard specified in the laboratory records were each prepared at 50 µg mL−1 in deionized water. All stock and working solutions were stored at 4 °C until use.

Preparation of dosing formulations

GFP (3.75, 7.50, or 12.50 g) was added to 100 mL of normal saline to obtain nominal concentrations of 37.50, 75.00, and 125.00 mg mL−1, respectively. Each preparation was ultrasonicated for 1 h; the procedure was repeated three times, and the resulting liquid fractions were combined after filtration. Simvastatin (90.00 mg) and fenofibrate (9.00 mg) were separately dispersed in 100 mL of normal saline; the source records report nominal concentrations of 0.9 and 0.09 mg mL−1, respectively.

Dosing preparations were freshly prepared or stored under the conditions documented in the original study records.

Establishment of hyperlipidemia and treatment design

Thirty-five rats were randomly allocated to a normal control group (NG; n = 5) or an HFD-fed cohort (n = 30). The NG group received standard chow, whereas the HFD-fed cohort received the high-fat diet for 6 weeks. After a 12 h fast, blood was collected from the retro-orbital venous plexus, and serum TC, TG, HDL-C, and LDL-C were measured to confirm the model.

The HFD-fed rats were then randomized into six groups (n = 5 per group): untreated HFD model, GFP low-dose (GFP-L), GFP medium-dose (GFP-M), GFP high-dose (GFP-H), simvastatin (Sim), and fenofibrate (Fen).

GFP was administered by oral gavage at 150, 300, or 500 mg kg−1 three times daily. Simvastatin was administered at 0.909 mg kg−1 once daily, and fenofibrate was administered at 9 mg kg−1 three times daily. The NG and HFD groups received an equivalent volume of normal saline.

Treatment continued for 2 consecutive weeks. The NG group remained on standard chow, whereas all other groups continued to receive the high-fat diet. Body weight was recorded during the study.

Untargeted metabolomics was performed on samples from the NG, HFD, GFP-H, Sim, and Fen groups.

Sample collection and histopathology

At the end of the 6 week modeling period, rats in the NG and HFD groups were fasted for 12 h with free access to water. Blood was collected from the retro-orbital venous plexus and centrifuged at 3000 rpm for 10 min at 4 °C; serum was stored at −80 °C. After the 2 week intervention, all rats were fasted for 12 h and anesthetized with 25% urethane.

Blood (approximately 5 mL) was collected from the abdominal aorta and centrifuged at 3000 rpm for 10 min at 4 °C. Serum aliquots were stored at −80 °C until analysis.

Livers were excised, rinsed with precooled sterile saline, blotted dry, and weighed. A tissue block (approximately 1 cm × 1 cm × 0.5 cm) was collected from the right hepatic lobe, fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histological changes were evaluated by light microscopy.

Urine and feces were collected over 12 h after the intervention. Urine was centrifuged at 13 000 rpm for 10 min, filtered through a 0.45 µm membrane, and stored at −80 °C. Fecal samples were stored at −80 °C until extraction.

Biochemical, organ-index, and atherosclerosis-index analyses

Serum TC, TG, HDL-C, LDL-C, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured using routine biochemical methods. The liver index was calculated as liver weight/body weight × 100%. The atherosclerosis index (AI) was calculated as (TC – HDL-C)/HDL-C.

Gastrodin PK/PD study

A separate cohort of six HFD-induced hyperlipidemic rats was fasted for 12 h before oral administration of gastrodin (25 mg kg−1). Blood samples (approximately 0.5 mL) were collected before dosing and at 5, 15, 25, 50, 75, 120, 150, 240, 360, 480, 720, and 1440 min after administration. Samples were collected into heparinized tubes and centrifuged at 3500 rpm for 10 min.

Plasma was stored at −80 °C. Isotonic saline was administered during serial sampling to support fluid replacement.

Sample preparation for untargeted metabolomics

Serum samples were thawed at 4 °C. Serum (100 µL) was mixed with 400 µL of methanol, vortexed for 5 min, and held at 4 °C for 30 min. After solvent removal in a vacuum concentrator at 45 °C, the residue was reconstituted in 300 µL of acetonitrile and centrifuged at 13 000 rpm for 10 min at 4 °C.

The supernatant was used for analysis. Equal aliquots from all serum samples were pooled to prepare a quality-control (QC) sample. The QC sample was injected five times at the beginning of the sequence and once after every five study samples.

Urine samples were thawed at 4 °C and centrifuged at 13 000 rpm for 10 min. The supernatant was analyzed directly, and equal aliquots were pooled to prepare a urine QC sample. Fecal material was extracted with four volumes of methanol in an ice-water bath, vortexed for 5 min, sonicated for 20 min, and centrifuged at 13 000 rpm for 10 min at 4 °C.

The supernatant was filtered through a 0.45 µm membrane. Pooled QC samples were prepared and analyzed using the same injection schedule as the serum QC samples.

Plasma sample preparation for targeted LC-MS/MS

Blank plasma (100 µL) was spiked with 10 µL of water, 10 µL of each internal-standard solution, and appropriate volumes of gastrodin and endogenous-metabolite working solutions. After vortex mixing, 500 µL of methanol–acetonitrile (1 : 4, v/v) was added. The mixture was vortexed for 90 s and evaporated to dryness in a vacuum concentrator at 45 °C.

The residue was reconstituted in 300 µL of acetonitrile, centrifuged at 10 000 rpm for 10 min at 4 °C, filtered, and transferred for LC-MS/MS analysis. Plasma samples collected after gastrodin administration were processed using the same procedure. Gastrodin, oleamide, kynurenic acid, l-phenylalanine, phenylacetylglycine (phenaceturic acid), and taurine were quantified at each time point.

Untargeted LC-high-resolution MS conditions

Chromatographic separation was performed on an ACQUITY UPLC BEH C18 column (2.1 × 100 mm, 1.7 µm; Waters) at 30 °C. The autosampler was maintained at 4 °C, and the injection volume was 10 µL. Mobile phases A and B were 0.1% formic acid in water and acetonitrile, respectively.

For urine, the gradient was 5–8% B at 0–2 min, 8–65% B at 2–8 min, 65–80% B at 8–13 min, 80–86% B at 13–15 min, 86–95% B at 15–18 min, and 95–5% B at 18–20 min. For serum and feces, the gradient was 5–8% B at 0–2 min, 8–65% B at 2–5 min, 65–80% B at 5–9 min, 80–86% B at 9–13 min, 86–95% B at 13–15 min, and 95–5% B at 15–26 min.

The Orbitrap system was operated with heated electrospray ionization in positive and negative ion modes. Spray voltages were 3.5 kV and 2.5 kV, respectively. The vaporizer and ion-transfer-tube temperatures were 350 and 325 °C.

Sheath and auxiliary gas settings were 50 and 10 arbitrary units. Full-scan/data-dependent MS2 acquisition was performed over m/z 100–1500. Full-scan resolution was 120 000, the RF lens was set to 70%, and the mass tolerance was 10 ppm.

Data-dependent MS2 resolution was 15 000, with a 2 m/z isolation window and normalized HCD collision energy of 50%.

Targeted LC-MS/MS conditions

Targeted analyses were performed on an Atlantis T3 column (2.1 × 150 mm, 3 µm; Waters) at 40 °C. The flow rate was 0.3 mL min−1, and the injection volume was 10 µL. Mobile phases A and B were 0.1% formic acid in water and acetonitrile, respectively.

The gradient was 10% B at 0–1.6 min, 10–90% B at 1.6–3 min, 90% B at 3–5 min, 90–10% B at 5–7 min, and 10% B at 7–8 min. The triple-quadrupole mass spectrometer was operated in multiple-reaction-monitoring mode with positive- and negative-ion detection. Compound-specific transitions and source parameters are provided in Table S1.

Metabolomic data processing and metabolite annotation

Raw files were inspected using FreeStyle and processed in Compound Discoverer 3.3 for peak detection, retention-time alignment, and feature extraction. Features with m/z ≤ 85 or a maximum peak area ≤100 000 were excluded. Candidate molecular formulas and metabolite identities were assigned from accurate mass (within 5 ppm), retention behavior, isotopic patterns, and MS/MS fragmentation by searching HMDB, ChemSpider, mzCloud, and the relevant literature.

Metabolites not confirmed using authentic reference standards were reported as putative annotations.

The processed feature matrix was imported into SIMCA 14.1 for principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS–DA). Model performance was evaluated using R2X, R2Y, Q2, and permutation testing. Differential features were screened using a variable-importance-in-projection value >1 and a two-sided p value < 0.05.

Differential metabolites were mapped to pathways using KEGG and MetaboAnalyst 6.0; pathways with an impact value >0.1 and p < 0.05 were considered prominent. Pearson correlation analysis was used to explore associations among differential metabolites across serum, urine, and feces.

Pharmacokinetic and PK/PD modeling

Gastrodin plasma concentration–time data were analyzed in Phoenix 8.1 to estimate pharmacokinetic parameters. Effect-time profiles were generated for oleamide, kynurenic acid, l-phenylalanine, phenylacetylglycine, and taurine. A semi-compartmental effect-compartment approach was used to estimate the effect-site concentration (Ce).

One-, two-, and three-compartment structures were compared using −2 log-likelihood (−2LL), Akaike information criterion (AIC), and Bayesian information criterion (BIC); the two-compartment model provided the best fit. Concentration-effect relationships were evaluated using a direct Emax model, E = Emax × Ce/(EC50 + Ce), and clockwise or counterclockwise hysteresis was assessed graphically.

Statistical analysis

Data are expressed as the mean ± standard deviation. Two-group comparisons were performed using student's t-test, and multiple-group comparisons were performed using one-way analysis of variance. All tests were two-sided, and p < 0.05 was considered statistically significant.

Multivariate metabolomic analyses were performed as described above.

Results and discussion

Model validation and effects of GFP on biochemical and histological outcomes

After 6 weeks of HFD feeding, serum TC, TG, and LDL-C concentrations were higher in HFD-fed rats than in NG rats (TC: 3.53 ± 0.13 vs. 2.27 ± 0.22 mmol L−1; TG: 2.44 ± 0.12 vs. 1.63 ± 0.17 mmol L−1; LDL-C: 1.03 ± 0.05 vs.

0.50 ± 0.07 mmol L−1), whereas HDL-C was lower (0.77 ± 0.04 vs. 1.24 ± 0.05 mmol L−1). The differences were significant for TC, LDL-C, and HDL-C at p < 0.001 and for TG at p < 0.01 (Table S3).

These biochemical abnormalities confirmed the establishment of HFD-induced hyperlipidemia.

Following the subsequent 2 week intervention, GFP-M and GFP-H improved the serum lipid profile compared with the untreated HFD group. At week 8, the GFP-H group had lower TC (1.26 ± 0.17 vs. 1.71 ± 0.25 mmol L−1), TG (0.59 ± 0.10 vs.

0.91 ± 0.13 mmol L−1), and LDL-C (0.47 ± 0.05 vs. 0.68 ± 0.10 mmol L−1), together with higher HDL-C (0.45 ± 0.04 vs. 0.29 ± 0.03 mmol L; all p < 0.001).

ALT and AST activities were also significantly lower in the GFP-M and GFP-H groups than in the HFD group (Table S4).

At the end of the intervention, the HFD group had a higher liver index and atherosclerosis index than the NG group (both p < 0.001). Both indices were lower in all GFP-treated groups than in the HFD group (all p < 0.001). In the GFP-H group, the liver index was 3.62 ± 0.04%, compared with 4.51 ± 0.02% in the HFD group, and the atherosclerosis index was 1.82 ± 0.21, compared with 5.07 ± 1.51 (Table S2).

The body-weight trajectories and final body weights are presented in Fig. 1IB and IA, respectively. Mean final body weights were numerically lower in the GFP-treated and positive-control groups than in the untreated HFD group.

Qualitative examination of liver sections showed preserved hepatic architecture in NG rats and pronounced hepatocellular vacuolation and architectural disruption in HFD rats. These changes were less pronounced in representative GFP-treated sections, particularly in the GFP-H group (Fig. 1II).

Metabolic profiles and analytical stability

Representative total-ion chromatograms of serum, urine, and fecal extracts showed broadly similar chromatographic contours across groups but clear differences in the intensity of multiple features (Fig. 2I). Pooled QC injections clustered tightly in PCA score plots, indicating stable chromatographic and mass-spectrometric performance over the analytical sequence.

The NG, HFD, GFP-H, Sim, and Fen groups were separated in the PCA space for all three matrices in both ionization modes, suggesting substantial diet- and treatment-associated metabolic variation (Fig. 2II).

OPLS–DA modeling and permutation validation

Supervised OPLS–DA further distinguished the NG and HFD groups and separated the HFD group from each treatment group (SI Fig. S1–S3). For urine, Q2 values ranged from 0.471 to 0.994 across pairwise models; for feces, Q2 values ranged from 0.936 to 0.993; and for serum, Q2 values ranged from 0.959 to 0.999.

Permutation testing generated negative Q2 values for all comparisons, ranging from −3.03 to −0.0835. These results supported the internal validity of the models, although the high classification performance was interpreted cautiously because each group contained only five animals.

Differential metabolites restored by GFP

Using VIP > 1 and p < 0.05, 42 urinary features (34 increased and 8 decreased), 32 fecal features (6 increased and 26 decreased), and 49 serum features (14 increased and 35 decreased) differed between the HFD and NG groups. After high-dose GFP treatment, 22 urinary features (10 increased and 12 decreased), 26 fecal features (7 increased and 19 decreased), and 42 serum features (23 increased and 19 decreased) differed from the untreated HFD group.

Intersection analysis identified 14 urinary, 8 fecal, and 16 serum metabolites that were disturbed by the high-fat diet and shifted in the opposite direction after GFP-H treatment. Their accurate masses, retention times, proposed identities, ionization modes, and relative changes are summarized in Tables 1–3. Heatmap visualization showed that the GFP-H metabolic pattern was generally displaced away from the HFD pattern and toward the NG pattern (Fig.

3).

Metabolic pathway enrichment

Urinary metabolites restored by GFP were primarily associated with phenylalanine, tyrosine, and tryptophan biosynthesis and with phenylalanine metabolism (Fig. 4a and b). Fecal metabolites were enriched in phenylalanine, tyrosine, and tryptophan biosynthesis, taurine and hypotaurine metabolism, and phenylalanine metabolism (Fig.

4c and d). Serum metabolites mapped mainly to phenylalanine, tyrosine, and tryptophan biosynthesis, taurine and hypotaurine metabolism, phenylalanine metabolism, and the tricarboxylic acid (TCA) cycle (Fig. 4e and f).

Together, the pathway results indicate that GFP influenced interconnected amino acid, bile acid-related, and energy metabolic processes.

Cross-matrix correlations

Pearson correlation analysis was used to explore coordinated changes among the candidate biomarkers. Sixty-nine significant metabolite pairs were identified between urine and feces, 10 between urine and serum, and 19 between serum and feces (Fig. 5).

These associations identify candidate cross-matrix relationships for further study but do not, by themselves, demonstrate biological coupling or causal interactions among the matrices.

Pharmacokinetics of gastrodin in hyperlipidemic rats

Gastrodin was detectable in plasma 5 min after oral administration, indicating rapid absorption. The mean plasma concentration reached a maximum at approximately 75 min and approached the lower limit of quantification by 24 h (Fig. 6 and SI Table S5).

The mean concentration–time profile showed a secondary rise or shoulder. This biphasic pattern may reflect delayed absorption, distributional processes, or enterohepatic recirculation; however, these possibilities were not tested directly.

Temporal profiles of metabolic effect markers

Oleamide, kynurenic acid, l-phenylalanine, phenylacetylglycine, and taurine were selected as pharmacodynamic markers because their levels were substantially altered by hyperlipidemia and shifted after GFP treatment. Gastrodin reached its maximum plasma concentration at approximately 75 min, whereas most endogenous markers reached a maximum or minimum response at approximately 240 or 720 min before gradually returning toward baseline (Fig. 7). l-Phenylalanine, kynurenic acid, and phenylacetylglycine displayed multi-peak effect–time profiles.

The delayed response relative to gastrodin exposure is compatible with an indirect metabolic effect, distributional delay, or contribution from downstream metabolites.

Effect-compartment and integrated PK/PD modeling

Effect-site concentration–effect plots showed hysteresis for all five markers (Fig. 8), indicating that measured plasma gastrodin concentrations were not in instantaneous equilibrium with the metabolic responses. Pearson correlation analysis showed that plasma gastrodin concentrations were positively correlated with l-phenylalanine (r = 0.33) and phenylacetylglycine (phenaceturic acid; r = 0.18), and negatively correlated with taurine (r = −0.26), oleamide (r = −0.29), and kynurenic acid (r = −0.15).

These relatively small correlation coefficients indicate weak linear associations between gastrodin concentrations and the selected metabolic markers.

The fitted Emax relationships were as follows: oleamide, E = 7.69Ce/(163 047 + Ce); kynurenic acid, E = 0.0077Ce/(31.25 + Ce); l-phenylalanine, E = 2.54Ce/(4.82 + Ce); phenylacetylglycine, E = 10.30Ce/(215.45 + Ce); and taurine, E = 0.0011Ce/(105.76 + Ce). The two-compartment model provided lower −2LL, AIC, and BIC values than the alternative structures, supporting its selection (SI Table S6). These models describe exposure-response associations but do not establish that gastrodin alone generated the full metabolic effect of GFP.

Discussion

This study used biochemical testing, liver histology, multi-matrix metabolomics, and gastrodin PK/PD modeling to characterize the response to GFP in HFD-fed rats. The principal findings were that GFP improved the serum lipid profile and liver injury indices, attenuated hepatic pathological changes, and shifted a subset of diet-disrupted metabolites toward normal levels. The metabolic response converged on phenylalanine-related pathways, taurine and hypotaurine metabolism, and the TCA cycle.

The PK/PD analysis further showed that changes in selected endogenous metabolites occurred later than the peak systemic exposure to gastrodin, supporting an indirect and temporally distributed mechanism. The two-week intervention period is a limitation of this study. Previous research demonstrated improvements in serum cholesterol and hepatic lipid accumulation following four weeks of G. elata extract administration in HFD-fed rats.16 Although the present study detected improvements in lipid profiles, hepatic histology, and selected metabolic disturbances after two weeks of GFP treatment, these findings indicate a short-term response and do not establish complete or sustained metabolic normalization.

Longer-duration studies with additional sampling time points and post-treatment follow-up are needed to characterize the progression and persistence of these effects.

The observed biochemical and histological improvements are consistent with previous reports of metabolic activity for G. elata. Water or ethanol extracts have been reported to reduce body fat, improve insulin sensitivity, ameliorate fructose-induced dyslipidemia and endothelial dysfunction, and improve lipid accumulation in diet-fed rodents.17,18 More recent work also suggests that G. elata can influence gut microbial composition, bile acid profiles, and inflammation in high-fat-diet models.19,20 The present data extend these observations by showing coordinated metabolic changes across serum, urine, and feces rather than focusing on a single tissue or pathway.

Phenylalanine metabolism was the most consistent pathway across the three matrices. Aromatic amino acids are linked to hepatic energy metabolism, microbial co-metabolism, and the generation of host-microbial conjugates such as phenylacetylglycine. In HFD models, disruption of amino acid handling commonly accompanies altered lipid oxidation and insulin sensitivity.21,22 The parallel restoration of l-phenylalanine and phenylacetylglycine therefore suggests that GFP may influence both hepatic amino acid utilization and intestinal microbial metabolism.

However, because the metabolites were identified mainly by accurate mass and MS/MS library matching, targeted confirmation and isotope-tracing experiments would be required to establish pathway flux.

Taurine and hypotaurine metabolism was enriched in feces and serum. Taurine participates in bile acid conjugation and can influence cholesterol elimination through bile acid synthesis and fecal excretion.23 Botanical polysaccharides and other food-derived compounds can also modulate the FXR-bile acid axis in hyperlipidemia.24 The fecal–serum association observed here is therefore biologically compatible with altered enterohepatic and intestinal metabolism. Nevertheless, the current experiment did not quantify a complete bile acid panel or characterize the gut microbiota, so the proposed connection among GFP, taurine, bile acids, and microbial activity remains a testable mechanism rather than a demonstrated causal pathway.

The serum enrichment of the TCA cycle indicates that the lipid-lowering response was accompanied by changes in central energy metabolism. HFD-induced hyperlipidemia is associated with broad perturbations in glycerophospholipids, fatty acids, sphingolipids, and mitochondrial metabolism.25–27 Restoration of TCA-cycle-related metabolites may reflect improved hepatic substrate handling and reduced metabolic overload. The effects on oleamide and other lipid-related metabolites further support remodeling of lipid signaling, although the present dataset does not distinguish whether these changes arose directly from GFP constituents or secondarily from improved systemic lipid status.

The PK/PD component adds temporal context to the metabolomic findings. Gastrodin was rapidly absorbed, whereas the metabolic markers generally reached their maximum or minimum responses several hours later and exhibited hysteresis. This pattern is consistent with indirect responses involving effect-site distribution, regulation of metabolic enzymes, conversion to downstream metabolites, or multistep signaling.

Gastrodin has been reported to improve glucolipid metabolism and insulin signaling and is a rational marker constituent for G. elata. Nevertheless, GFP contains multiple bioactive constituents, including phenolics and polysaccharides. The divergent associations between gastrodin and the five metabolic markers therefore argue against a simple one-compound explanation and may reflect composite effects of the whole preparation.

Accordingly, the PK/PD results should be interpreted as exposure–response associations for a representative constituent rather than as evidence that gastrodin alone mediates the activity of GFP.

Several limitations should be considered. First, the efficacy groups contained only five animals, limiting statistical power and increasing the risk of unstable multivariate separation. Second, an a priori sample-size calculation, blinded outcome assessment, and detailed post hoc procedures were not reported.

Third, most metabolite identities were putative, and false-discovery-rate correction was not described for the feature-level analyses. Fourth, the composition and batch consistency of GFP were not comprehensively characterized, and the relationship among the administered fine-powder preparation, the dosing liquid, and the gastrodin dose used in the separate PK study requires clarification. Fifth, full validation parameters for the targeted LC-MS/MS method should be reported.

Finally, the study did not include microbiome analysis, targeted bile acid profiling, hepatic metabolomics, or mechanistic intervention experiments. These issues should be addressed before the findings are translated into claims of functional-food efficacy in humans.

Conclusion

GFP attenuated HFD-induced dyslipidemia and hepatic injury in rats and partially ameliorated metabolic disturbances in serum, urine, and feces. The principal associated pathways involved phenylalanine metabolism, taurine and hypotaurine metabolism, and the tricarboxylic acid cycle. Gastrodin exposure was temporally associated with delayed changes in five metabolic markers, consistent with an indirect and multistep response.

These findings support further investigation of G. elata as a candidate functional-food ingredient for lipid-metabolism management, while underscoring the need for rigorous compositional standardization, targeted metabolite validation, and mechanistic confirmation.

Conflicts of interest

The authors declare no conflicts of interest.

Nomenclature

Supplementary Material

Related articles

PubMed

A Multimodal Neuroimaging Study of Hyperlipidemia-Induced Abnormal Spontaneous Brain Activity and Cognitive Decline.

ABSTRACT Objective To investigate multidomain cognitive performance in older adults with hyperlipidemia and its associations with alterations in spontaneous brain activity and functional connectivity (FC). Methods A total of 104 participants were recruited, comprising 50 hyperlipidemia patients and 54 healthy controls. Comprehensive psychological assessments were conducted, and resting‐state functional magnetic resonance imaging (rs‐fMRI) data were collected from both groups. Amplitude of lo...

PubMed

Causal effects between gut microbiology and hyperlipidemia: A 2-sample Mendelian randomization study.

Recent studies have confirmed the connection between gut microbiota (GM) and hyperlipidemia. This study used the Mendelian randomization (MR) technique to explore the association between GM and hyperlipidemia. MR was used to examine data derived from a genome-wide association study that combined data from 211 intestinal microbiota and hyperlipidemia. Five statistical tools were used for statistical analyses, including the MR-Egger method, the weighted median method, the inverse variance weighted...